{'fraction_non_alphanumeric': 0.031073446327683617, 'fraction_numerical': 0.002824858757062147, 'mean_word_length': 5.752380952380952, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Serum fetuin‐A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes

Objective  Hepatic steatosis is associated with an increased risk of diabetes. Although the levels of serum fetuin‐A, a liver‐derived glycoprotein that impairs insulin signalling, are positively correlated with hepatic steatosis, the levels of fetuin‐A in subjects with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed type 2 diabetes (NDD) have not been established. The aim of this study is to investigate the relationship among serum fetuin‐A concentrations, IFG, IGT and NDD in Chinese subjects without nonalcoholic fatty liver disease (NAFLD).